Cellectis - ADR
NASDAQ:CLLS
| Market Cap (Intraday) | 183.57M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.68 |
| 50-Day MA | $2.25 |
| 200-Day MA | $1.73 |
Cellectis - ADR Stock, NASDAQ:CLLS
8, rue de la Croix Jarry, Paris, Ile-de-France 75013
France
Phone: +33.1.81.69.16.00
Number of Employees: 222
Description
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andr�© Choulika on February 20, 1999 and is headquartered in Paris, France.